Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan

NCT03311464 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03311464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03311464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
October 27, 2017
Completion date
April 21, 2020
Enrollment
22 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

pyoderma gangrenosum